Trevi Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Corporate Update on November 6, 2024
Trevi Therapeutics (NASDAQ: TRVI) has announced it will report its Q3 2024 financial results and provide a corporate update on November 6, 2024, at 4:30 p.m. ET. The company, which is developing Haduvio™ (oral nalbuphine ER) for chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), will host a conference call and webcast. Participants can join via phone at (877) 870 4263 (domestic) or (412) 317 0790 (international). The webcast will be available on the company's website and archived for 30 days.
Trevi Therapeutics (NASDAQ: TRVI) ha annunciato che riporterà i suoi risultati finanziari del terzo trimestre 2024 e fornirà un aggiornamento aziendale il 6 novembre 2024 alle 16:30 ET. L'azienda, che sta sviluppando Haduvio™ (nalbufina orale ER) per la tosse cronica nella fibrosi polmonare idiopatica (IPF) e la tosse cronica refrattaria (RCC), ospiterà una conferenza telefonica e una trasmissione in streaming. I partecipanti possono unirsi per telefono al numero (877) 870 4263 (nazionale) o (412) 317 0790 (internazionale). La trasmissione in streaming sarà disponibile sul sito web dell'azienda e archiviata per 30 giorni.
Trevi Therapeutics (NASDAQ: TRVI) ha anunciado que presentará sus resultados financieros del tercer trimestre de 2024 y proporcionará una actualización corporativa el 6 de noviembre de 2024 a las 4:30 p.m. ET. La compañía, que está desarrollando Haduvio™ (nalbufina oral ER) para la tos crónica en fibrosis pulmonar idiopática (IPF) y tos crónica refractaria (RCC), llevará a cabo una conferencia telefónica y una transmisión por webcast. Los participantes pueden unirse por teléfono al (877) 870 4263 (nacional) o al (412) 317 0790 (internacional). La transmisión estará disponible en el sitio web de la compañía y archivada durante 30 días.
Trevi Therapeutics (NASDAQ: TRVI)는 2024년 3분기 재무 결과를 보고하고 기업 업데이트를 2024년 11월 6일 오후 4시 30분 ET에 제공할 것이라고 발표했습니다. 만성 기침을 치료하기 위해 Haduvio™ (경구용 날부핀 ER)을 개발 중인 이 회사는 전화 회의와 웹 세미나를 주최할 예정입니다. 참여자는 (877) 870 4263 (국내) 또는 (412) 317 0790 (국제)로 전화하여 참석할 수 있습니다. 웹 세미나는 회사 웹사이트에서 제공되며 30일 동안 아카이브됩니다.
Trevi Therapeutics (NASDAQ: TRVI) a annoncé qu'elle publiera ses résultats financiers du troisième trimestre 2024 et fournira une mise à jour de l'entreprise le 6 novembre 2024 à 16h30 ET. L'entreprise, qui développe Haduvio™ (nalbuphine orale ER) pour la toux chronique dans la fibrose pulmonaire idiopathique (IPF) et la toux chronique réfractaire (RCC), animera une téléconférence et un webinaire. Les participants peuvent se joindre par téléphone au (877) 870 4263 (national) ou au (412) 317 0790 (international). Le webinaire sera disponible sur le site web de l'entreprise et archivé pendant 30 jours.
Trevi Therapeutics (NASDAQ: TRVI) hat angekündigt, dass es seine Finanzergebnisse für das 3. Quartal 2024 veröffentlichen und ein Unternehmensupdate am 6. November 2024 um 16:30 Uhr ET geben wird. Das Unternehmen, das Haduvio™ (orale Nalbufin ER) zur Behandlung von chronischem Husten bei idiopathischer Lungenfibrose (IPF) und refraktärem chronischem Husten (RCC) entwickelt, wird eine Telefonkonferenz und ein Webcast veranstalten. Teilnehmer können sich telefonisch unter (877) 870 4263 (inländisch) oder (412) 317 0790 (international) dazuschalten. Der Webcast wird auf der Unternehmenswebsite verfügbar sein und 30 Tage lang archiviert.
- None.
- None.
Conference call and webcast to be held at 4:30 p.m. ET
To participate in the live conference call by phone, please dial (877) 870 4263 (domestic) or (412) 317 0790 (international) and ask to join the Trevi Therapeutics call. No code is necessary for access. A live audio webcast will be accessible from the 'Investors & News' section on the Company's website at www.TreviTherapeutics.com. An archived replay of the webcast will also be available for 30 days on the Company's website following the event.
About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine extended-release (ER)) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). Haduvio acts on the cough reflex arc both centrally and peripherally as a kappa agonist and a mu antagonist (KAMA), which are opioid receptors that play a key role in controlling cough hypersensitivity. Nalbuphine is not scheduled by the
The impact of chronic cough is significant and often leads to a decline in patients' social, physical, and psychological quality of life. In IPF, chronic cough may lead to worsening disease and may be associated with a higher risk of progression, death, or need for lung transplant. There are no approved therapies for the treatment of chronic cough in IPF and current treatment options provide minimal benefit to patients. Chronic cough affects up to
Trevi intends to propose Haduvio as the trade name for oral nalbuphine ER. Its safety and efficacy have not been evaluated by any regulatory authority.
For more information, visit www.TreviTherapeutics.com and follow Trevi on X (formerly Twitter) and LinkedIn.
Investor Contact
Katie Barrett
Trevi Therapeutics, Inc.
203-304-2499
k.barrett@trevitherapeutics.com
Media Contact
Rosalia Scampoli
914-815-1465
rscampoli@marketcompr.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/trevi-therapeutics-to-report-third-quarter-2024-financial-results-and-provide-a-corporate-update-on-november-6-2024-302291657.html
SOURCE Trevi Therapeutics, Inc.
FAQ
When will Trevi Therapeutics (TRVI) report Q3 2024 earnings?
How can investors join Trevi Therapeutics (TRVI) Q3 2024 earnings call?
What treatments is Trevi Therapeutics (TRVI) currently developing?
